Registry following people having heart artery procedures called PCI in Korea
Records outcomes of adults and others undergoing stent-based coronary artery opening procedures.
Key facts
- Who runs it
- Yonsei University
- Where
- Chuncheon, Gangneung, and Wŏnju, South KoreaSee the 4 sites
- Trial code
- Registry title
- Gangwon PCI Prospective Registry
- Status
- Recruiting
- People taking part
- 10,000 people, planned
- Started
- 1 Jan 2013
- Expected to end
- 31 Dec 2031
- Type of study
- Observational
- Treatments tested
- Percutaneous Coronary Intervention (PCI)
- Record updated
- 7 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people of any age who are having a stent or balloon procedure (PCI) on their heart arteries at one of the four taking-part hospitals in Gangwon Province, Korea.
- Age
- Any age
- Sex
- All sexes
- Disease stage
- Coronary artery disease treated with percutaneous coronary intervention (PCI). No specific stage is named.
Main reasons for not taking part
- People who refuse or withdraw their consent, when consent is required
- People who did not have a PCI during the hospital stay in question
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Patients of any age undergoing percutaneous coronary intervention (PCI) at a participating hospital during the study period
- Written informed consent is obtained from the patient or a legally authorized representative before collection of study data, unless the requirement for informed consent is waived by the Institutional Review Board
Who cannot take part
- Refusal or withdrawal of informed consent, when informed consent is required
- No PCI performed during the index hospital encounter
Where in South Korea
- Chuncheon Hallym University HospitalChuncheon, South KoreaContact: Hyun Hee Choi, M.D.Taking people
- Kangwon National University HospitalChuncheon, South KoreaContact: Bong-Ki Lee, M.D., Ph.D.Taking people
- Gangneung Asan HospitalGangneung, South KoreaContact: Hanbit Park, M.D., Ph.D.Taking people
- Wonju Severance Christian HospitalWŏnju, South KoreaContact: Young Jin Youn, M.D., Ph.D.Taking people
About the trial
What the trial wants to find out
This prospective, multicenter registry will consecutively enroll patients of all ages undergoing percutaneous coronary intervention (PCI) at four university hospitals in Gangwon Province, Republic of Korea.
Read full original descriptionShow less
The study will describe contemporary clinical, procedural, and medication treatment patterns and assess 1-year clinical outcomes in routine practice.
The primary outcome is patient-oriented composite outcome (POCO), defined as all-cause death, any myocardial infarction, or any repeat revascularization.
No study-specific intervention will be assigned.
The group in the trial
- Patients undergoing PCI
All consecutively enrolled patients undergoing percutaneous coronary intervention at the participating hospitals. PCI is performed as part of routine clinical care and is not assigned by the study protocol.
Treatment: Percutaneous Coronary Intervention (PCI)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Prospective Registry for Patients Undergoing Coronary Angiography and Percutaneous Coronary Intervention in Gangwon Province
- Plain-language title
- Registry following people having heart artery procedures called PCI in KoreaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Safety and Efficacy of Two Ultrathin Biodegradable Polymer Sirolimus-Eluting Stents in Real-World Practice: Genoss DES Stents Versus Orsiro Stents From a Prospective Registry.Clinical cardiology, 2024
- Impact of the ultra-long 48 mm drug-eluting stent on procedural and clinical outcomes in patients with diffuse long coronary artery disease.Clinical cardiology, 2023
- Record updated
- 7 October 2026